Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

624

Enrollment

INDUSTRY

Sponsor class

Conditions

HER-2 Positive Breast Cancer
Metastatic Neoplasm

Interventions

BIOLOGICAL: Margetuximab
BIOLOGICAL: Trastuzumab
DRUG: Physician's choice of chemotherapy.

Sponsor

MacroGenics